Bitcoin Surpasses $100,000 While Morgan Stanley Intern Survey Shows Crypto Adoption Still Nascent
Bitcoin has crossed the $100,000 threshold in 2026, yet a recent Morgan Stanley survey indicates that cryptocurrency adoption remains limited among emerging finance professionals.
The investment bank polled over 500 summer interns in North America (June 10–27) and 147 in Europe (June 26–July 7). Findings show that only 18% of interns currently hold or use cryptocurrencies, up slightly from 13% last year. Interest in digital assets rose modestly to 26%, but the majority—55%—remain uninterested, down from 63% the previous year.
This cautious approach contrasts with growing institutional involvement in crypto markets. Since January 2025, eleven spot Bitcoin ETFs have attracted $53.7 billion, while Ether ETFs have drawn $12.4 billion, according to Farside Investors. Corporate treasuries are increasingly adding these assets to their portfolios.
Ether also recently hit a record high of over $4,800, highlighting renewed market enthusiasm.
AI Adoption Surges Among Interns
Artificial intelligence has seen widespread adoption, with 96% of U.S. interns and 91% of Europeans reporting some use of AI technologies. Most agree AI tools save time and are user-friendly, though 88% believe accuracy still needs improvement.
This mirrors trends on Wall Street, where top firms are expected to invest $650 billion in AI research and development this year.
Growing Interest and Caution Around Humanoids
The survey found significant interest in humanoid robots, with more than 60% of U.S. interns and nearly 70% of European interns expressing willingness to have a humanoid at home. Both groups see viable applications for these robots, which are expected to replace many human jobs.
However, only 36% of U.S. and 24% of European interns believe humanoids will positively impact society, reflecting a cautious outlook.
Morgan Stanley estimates the humanoid market could surpass $5 trillion by 2050, with over 1 billion units in operation—mostly for industrial and commercial use.
